Viking Therapeutics Inc (VKTX)
76.40
-3.17
(-3.98%)
USD |
NASDAQ |
May 01, 16:00
76.69
+0.29
(+0.38%)
After-Hours: 20:00
Viking Therapeutics Total Liabilities (Quarterly): 33.63M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 33.63M |
| December 31, 2023 | 20.07M |
| September 30, 2023 | 14.42M |
| June 30, 2023 | 14.58M |
| March 31, 2023 | 16.83M |
| December 31, 2022 | 23.21M |
| September 30, 2022 | 15.40M |
| June 30, 2022 | 16.28M |
| March 31, 2022 | 12.76M |
| December 31, 2021 | 8.778M |
| September 30, 2021 | 11.35M |
| June 30, 2021 | 12.87M |
| March 31, 2021 | 12.92M |
| December 31, 2020 | 12.16M |
| September 30, 2020 | 9.83M |
| June 30, 2020 | 9.251M |
| March 31, 2020 | 8.821M |
| December 31, 2019 | 7.137M |
| September 30, 2019 | 6.63M |
| June 30, 2019 | 6.139M |
| Date | Value |
|---|---|
| March 31, 2019 | 5.506M |
| December 31, 2018 | 4.562M |
| September 30, 2018 | 4.743M |
| June 30, 2018 | 4.105M |
| March 31, 2018 | 6.339M |
| December 31, 2017 | 8.657M |
| September 30, 2017 | 9.614M |
| June 30, 2017 | 7.733M |
| March 31, 2017 | 7.606M |
| December 31, 2016 | 6.493M |
| September 30, 2016 | 6.098M |
| June 30, 2016 | 5.764M |
| March 31, 2016 | 6.987M |
| December 31, 2015 | 6.714M |
| September 30, 2015 | 5.742M |
| June 30, 2015 | 4.876M |
| March 31, 2015 | 30.61M |
| December 31, 2014 | 25.17M |
| June 30, 2014 | 25.27M |
| March 31, 2014 | 0.7554M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
6.139M
Minimum
Jun 2019
33.63M
Maximum
Mar 2024
13.65M
Average
12.81M
Median
Total Liabilities (Quarterly) Benchmarks
| Eli Lilly and Co | 53.14B |
| Pfizer Inc | 137.21B |
| Madrigal Pharmaceuticals Inc | 235.21M |
| Akero Therapeutics Inc | 44.96M |
| Terns Pharmaceuticals Inc | 13.15M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 967.52M |
| Shareholders Equity (Quarterly) | 933.89M |